| Oct 22 |
Silence Therapeutics files for ordinary shares offering
|
| Sep 8 |
Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy'
|
| Sep 5 |
Silence: Additional siRNA Drug Data Leads To Next Stages Of Development
|
| Aug 27 |
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
|
| Aug 18 |
Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
|
| Aug 17 |
Silence Therapeutics Second Quarter 2024 Earnings: Misses Expectations
|
| Aug 16 |
Silence Therapeutics reports Q2 results
|
| Aug 15 |
Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
|
| Aug 7 |
The 3 Best Gene Editing Stocks to Buy in August 2024
|
| Jul 25 |
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
|
